Literature DB >> 25101690

Peptides, proteins and peptide/protein-polymer conjugates as drug delivery system.

Biswajit Mukherjee, Swapna D Karmakar, Chowdhury M Hossain, Sanchari Bhattacharya1.   

Abstract

In the last few decades, novel drug delivery strategies have been a big priority to the formulation scientists. Peptides and proteins have drawn a special attention for their wide scope in the area. Serum albumin, transferrin, recom- binant proteins, virus capsids etc. are used as carrier for drug and biomolecules. Conjugates of polymers with proteins have also shown strong potency in the field of drug delivery. Polyethylene glycol is one of the most successful polymers that has been used extensively to develop protein conjugated formulations. Besides, polyvinyl pyrrolidone, polylactic-co- glycolic acid, N-(2-hydroxypropyl) methacrylamide copolymer, polyglutamic acid have also been investigated. In this re- view, we will highlight on the most recent overview of various advantages, limitations and marketed products of proteins, peptides and protein/peptide-polymer conjugates as drug carriers, such products in clinical trials and their various uses in the field of modern drug delivery. Understanding the key features of these materials and the vigorous research in this field will develop new drug formulations that will combat various types of life-threatening diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25101690     DOI: 10.2174/0929866521666140804160907

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  2 in total

1.  Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Authors:  Kathleen N Moore; Hossein Borghaei; David M O'Malley; Woondong Jeong; Shelly M Seward; Todd M Bauer; Raymond P Perez; Ursula A Matulonis; Kelli L Running; Xiaoyan Zhang; Jose F Ponte; Rodrigo Ruiz-Soto; Michael J Birrer
Journal:  Cancer       Date:  2017-04-25       Impact factor: 6.860

2.  Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.

Authors:  Songtao Li; Hongling Zhao; Xiaoxia Mao; Yanfang Fan; Xiujun Liang; Ruxing Wang; Lijun Xiao; Jianping Wang; Qi Liu; Guiqin Zhao
Journal:  Pharm Res       Date:  2019-10-25       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.